Literature DB >> 20413666

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Craig B Reeder, Donna E Reece, Vishal Kukreti, Christine Chen, Suzanne Trudel, Kristina Laumann, Joseph Hentz, Nicholas A Pirooz, Jesus G Piza, Rodger Tiedemann, Joseph R Mikhael, Peter L Bergsagel, Jose F Leis, Rafael Fonseca, Alexander K Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20413666     DOI： 10.1182/blood-2010-02-271676

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  62 in total

Review 1.  Proteasome inhibitors in multiple myeloma: 10 years later.

Authors:  Philippe Moreau; Paul G Richardson; Michele Cavo; Robert Z Orlowski; Jesús F San Miguel; Antonio Palumbo; Jean-Luc Harousseau
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

Review 2.  Bortezomib combination therapy in multiple myeloma.

Authors:  Prashant Kapoor; Vijay Ramakrishnan; S Vincent Rajkumar
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Authors:  Arnaud Jaccard; Raymond L Comenzo; Parameswaran Hari; Philip N Hawkins; Murielle Roussel; Pierre Morel; Margaret Macro; Jean-Luc Pellegrin; Estibaliz Lazaro; Dania Mohty; Patrick Mercie; Olivier Decaux; Julian Gillmore; David Lavergne; Frank Bridoux; Ashutosh D Wechalekar; Christopher P Venner
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

4.  Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy.

Authors:  Yong Tang; Ye-Hua Yu; Yi-Yun Yao; Li-Fang Zou; Hong-Ju Dou; Lei Wang; Qi Zhu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-27       Impact factor: 0.900

Review 5.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

6.  Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Authors:  María-Victoria Mateos; Sara Bringhen; Paul G Richardson; Juan Jose Lahuerta; Alessandra Larocca; Albert Oriol; Mario Boccadoro; Ramón García-Sanz; Francesco Di Raimondo; Dixie-Lee Esseltine; Helgi van de Velde; Avinash Desai; Anil Londhe; Jesús F San Miguel; Antonio Palumbo
Journal:  Haematologica       Date:  2014-04-24       Impact factor: 9.941

7.  Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Authors:  Yun Xiang; Elizabeth R Remily-Wood; Vasco Oliveira; Danielle Yarde; Lili He; Jin Q Cheng; Linda Mathews; Kelly Boucher; Christopher Cubitt; Lia Perez; Ted J Gauthier; Steven A Eschrich; Kenneth H Shain; William S Dalton; Lori Hazlehurst; John M Koomen
Journal:  Mol Cell Proteomics       Date:  2011-08-16       Impact factor: 5.911

8.  CyBorD induction therapy in clinical practice.

Authors:  N Areethamsirikul; E Masih-Khan; C-M Chu; V Jimenez-Zepeda; D E Reece; S Trudel; V Kukreti; R Tiedemann; C Chen
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

9.  Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Authors:  Jatin J Shah; Edward A Stadtmauer; Rafat Abonour; Adam D Cohen; William I Bensinger; Cristina Gasparetto; Jonathan L Kaufman; Suzanne Lentzsch; Dan T Vogl; Christina L Gomes; Natalia Pascucci; David D Smith; Robert Z Orlowski; Brian G M Durie
Journal:  Blood       Date:  2015-09-17       Impact factor: 22.113

Review 10.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.